The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -116,803 |
| Depreciation and amortization expense | 6,381 |
| Noncash lease expense | 3,383 |
| Stock-based compensation expense | 14,267 |
| Loss on disposal of property and equipment | -103 |
| Net amortization of premiums and accretion discounts on investments | 4,093 |
| Amortization of deferred transaction costs | 43 |
| Prepaid expenses and other current assets | -1,681 |
| Other non-current assets | -308 |
| Accounts payable | 1,029 |
| Operating lease liability | -3,449 |
| Accrued and other current and non-current liabilities | 1,904 |
| Net cash used in operating activities | -95,246 |
| Purchases of short-term treasury securities | 140,869 |
| Maturities of short term treasury securities | -145,000 |
| Purchase of property and equipment | 1,738 |
| Net cash provided by (used in) investing activities | 2,393 |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs | 0 |
| Proceeds from issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs | 75,172 |
| Proceeds from exercise of stock options | 1 |
| Proceeds from employee stock purchase plan | 326 |
| Taxes withheld and paid related to net share settlement of equity awards | -104 |
| Principal payments on finance leases | 150 |
| Net cash provided by financing activities | 75,245 |
| Net change in cash, cash equivalents and restricted cash | -17,608 |
| Cash, cash equivalents at the beginning of the period | 59,398 |
| Cash, cash equivalents at the end of the period | 41,790 |
Adicet Bio, Inc. (ACET)
Adicet Bio, Inc. (ACET)